Published in Mov Disord on August 23, 2012
Levodopa-induced plasticity: a double-edged sword in Parkinson's disease? Philos Trans R Soc Lond B Biol Sci (2015) 0.89
PINK1 heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity. Mov Disord (2013) 0.88
Adult Conditional Knockout of PGC-1α Leads to Loss of Dopamine Neurons. eNeuro (2016) 0.82
Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition. Basal Ganglia (2013) 0.81
Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways. J Neurosci (2015) 0.78
Decoding the substrate supply to human neuronal nitric oxide synthase. PLoS One (2013) 0.78
Microbubble gas volume: A unifying dose parameter in blood-brain barrier opening by focused ultrasound. Theranostics (2017) 0.75
Effect of adenosine and adenosine receptor antagonist on Müller cell potassium channel in Rat chronic ocular hypertension models. Sci Rep (2015) 0.75
Salsalate treatment following traumatic brain injury reduces inflammation and promotes a neuroprotective and neurogenic transcriptional response with concomitant functional recovery. Brain Behav Immun (2016) 0.75
Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options. P T (2015) 0.75
Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science (2002) 8.41
Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain (1991) 8.16
Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci (2006) 4.98
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med (2010) 4.45
Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature (2007) 4.36
Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science (2002) 3.98
Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol (2006) 3.72
Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci (1995) 3.65
Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci (2007) 3.64
LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci (2006) 3.58
Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci U S A (2006) 3.41
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci (2003) 3.25
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci (2010) 3.14
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol (2011) 2.91
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J (2010) 2.43
The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol (2011) 2.42
Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A (2010) 2.34
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J (2009) 2.33
Apoptosis-inducing factor triggered by poly(ADP-ribose) polymerase and Bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia. J Neurosci (2005) 2.32
Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp Neurol (2009) 2.24
Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci (1997) 2.23
Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am J Pathol (2008) 2.15
Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum. Neuropharmacology (2010) 2.14
Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology (2008) 2.13
Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol (2004) 2.11
Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol (2007) 1.90
Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci U S A (1999) 1.88
Parthanatos, a messenger of death. Front Biosci (Landmark Ed) (2009) 1.84
Long-term Potentiation in the Striatum is Unmasked by Removing the Voltage-dependent Magnesium Block of NMDA Receptor Channels. Eur J Neurosci (1992) 1.80
Pathologically activated therapeutics for neuroprotection. Nat Rev Neurosci (2007) 1.77
The distinct role of medium spiny neurons and cholinergic interneurons in the D₂/A₂A receptor interaction in the striatum: implications for Parkinson's disease. J Neurosci (2011) 1.76
Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci Signal (2011) 1.73
Nitric oxide in neurodegeneration. Prog Brain Res (1998) 1.69
Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci U S A (2006) 1.66
Apoptosis-inducing factor is a key factor in neuronal cell death propagated by BAX-dependent and BAX-independent mechanisms. J Neurosci (2005) 1.58
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim Biophys Acta (2008) 1.55
Molecular and biochemical features of poly (ADP-ribose) metabolism. Mol Cell Biochem (1993) 1.52
LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet (2011) 1.52
Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience (2005) 1.51
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol (2010) 1.50
Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol (2008) 1.47
Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage. Proc Natl Acad Sci U S A (2011) 1.42
Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol Ther (2004) 1.38
Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. Nat Med (2011) 1.36
FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity. Nat Neurosci (2008) 1.36
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci (2006) 1.34
Deadly conversations: nuclear-mitochondrial cross-talk. J Bioenerg Biomembr (2004) 1.31
Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol (2011) 1.29
Striatal synaptic plasticity: implications for motor learning and Parkinson's disease. Mov Disord (2005) 1.26
Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Hum Mol Genet (2011) 1.21
A critical role of the nitric oxide/cGMP pathway in corticostriatal long-term depression. J Neurosci (1999) 1.18
Apoptosis inducing factor mediates caspase-independent 1-methyl-4-phenylpyridinium toxicity in dopaminergic cells. J Neurochem (2005) 1.16
Dopamine-dependent synaptic plasticity in striatum during in vivo development. Proc Natl Acad Sci U S A (2001) 1.16
Plasticity and repair in the post-ischemic brain. Neuropharmacology (2008) 1.16
Dopamine-dependent long-term depression is expressed in striatal spiny neurons of both direct and indirect pathways: implications for Parkinson's disease. J Neurosci (2011) 1.14
Synaptic plasticity in the ischaemic brain. Lancet Neurol (2003) 1.09
Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog Neurobiol (2007) 1.08
Roles of poly(ADP-ribosyl)ation and PARP in apoptosis, DNA repair, genomic stability and functions of p53 and E2F-1. Adv Enzyme Regul (2000) 1.08
Complex I: inhibitors, inhibition and neurodegeneration. Exp Neurol (2010) 1.08
Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. Neuropharmacology (2007) 1.07
Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J Pharmacol Exp Ther (2002) 1.07
Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology (2011) 1.07
Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J Neurosci (2004) 1.06
Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain (2010) 1.05
Unilateral dopamine denervation blocks corticostriatal LTP. J Neurophysiol (1999) 1.03
Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol (2000) 1.02
Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms. J Alzheimers Dis (2010) 1.01
Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J Neurosci (2010) 0.97
Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. Neurodegeneration (1996) 0.97
Differential structural plasticity of corticostriatal and thalamostriatal axo-spinous synapses in MPTP-treated Parkinsonian monkeys. J Comp Neurol (2011) 0.97
Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias. Neurobiol Aging (2011) 0.97
Role of nitric oxide on motor behavior. Cell Mol Neurobiol (2005) 0.97
Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients. PLoS One (2011) 0.95
NR2B subunit exerts a critical role in postischemic synaptic plasticity. Stroke (2006) 0.95
Synaptic dysfunction in Parkinson's disease. Biochem Soc Trans (2010) 0.95
Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol Dis (2005) 0.94
Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation. Eur J Neurosci (2004) 0.92
Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Eur J Neurosci (2008) 0.89
Nitric Oxide-Soluble Guanylyl Cyclase-Cyclic GMP Signaling in the Striatum: New Targets for the Treatment of Parkinson's Disease? Front Syst Neurosci (2011) 0.88
Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson's disease. J Neural Transm Suppl (2006) 0.88
Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models. Biochem Biophys Res Commun (2007) 0.87
Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease. Exp Neurol (2004) 0.87
Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. Brain Res Mol Brain Res (1998) 0.86
Neuroglial plasticity at striatal glutamatergic synapses in Parkinson's disease. Front Syst Neurosci (2011) 0.85
Epilepsy-induced abnormal striatal plasticity in Bassoon mutant mice. Eur J Neurosci (2009) 0.85
Mechanisms underlying altered striatal synaptic plasticity in old A53T-α synuclein overexpressing mice. Neurobiol Aging (2011) 0.84
Impaired plasticity at specific subset of striatal synapses in the Ts65Dn mouse model of Down syndrome. Biol Psychiatry (2009) 0.84
Striatum-hippocampus balance: from physiological behavior to interneuronal pathology. Prog Neurobiol (2011) 0.84
Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: from experimental models to neurodegenerative diseases. Biochim Biophys Acta (2009) 0.83
Adenosine A2a receptor antagonists attenuate striatal adaptations following dopamine depletion. Neurobiol Dis (2011) 0.83
Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinson's disease. Prog Brain Res (2010) 0.82
An update on adenosine A2A receptors as drug target in Parkinson's disease. CNS Neurol Disord Drug Targets (2011) 0.82
NADPH-diaphorase/nitric oxide synthase containing neurons in normal and Parkinson's disease putamen. J Neural Transm Park Dis Dement Sect (1994) 0.81
TrkB/BDNF-dependent striatal plasticity and behavior in a genetic model of epilepsy: modulation by valproic acid. Neuropsychopharmacology (2010) 0.77
A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity. Exp Neurol (2009) 0.77
Neuroscience: Brain's traffic lights. Nature (2010) 0.76
Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science (2002) 8.41
PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A (2009) 8.25
Molecular pathways of neurodegeneration in Parkinson's disease. Science (2003) 7.55
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A (2005) 6.98
Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci (2005) 5.93
Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci (2006) 5.32
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet (2007) 4.99
S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science (2004) 4.97
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med (2010) 4.45
PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell (2011) 4.00
Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci (2005) 3.92
Genetic animal models of Parkinson's disease. Neuron (2010) 3.86
Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol (2006) 3.72
Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci (2007) 3.64
Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci U S A (2006) 3.47
Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci U S A (2006) 3.41
Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A (2002) 3.33
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet (2004) 3.12
Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A (2005) 3.00
DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A (2007) 2.87
Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest (2006) 2.86
A hierarchical NGF signaling cascade controls Ret-dependent and Ret-independent events during development of nonpeptidergic DRG neurons. Neuron (2007) 2.83
Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet (2005) 2.72
Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. Nucleic Acids Res (2008) 2.70
Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat Cell Biol (2008) 2.56
Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene (2004) 2.52
Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci (2009) 2.47
Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J Cell Biol (2002) 2.47
Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A (2005) 2.45
Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Hum Mol Genet (2007) 2.44
Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet (2011) 2.29
Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J Biol Chem (2003) 2.26
Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp Neurol (2009) 2.24
Understanding microRNAs in neurodegeneration. Nat Rev Neurosci (2009) 2.22
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol (2012) 2.20
Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. Proc Natl Acad Sci U S A (2004) 2.20
Apoptosis-inducing factor substitutes for caspase executioners in NMDA-triggered excitotoxic neuronal death. J Neurosci (2004) 2.17
Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum Mol Genet (2005) 2.11
Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci (2005) 2.06
Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum Mol Genet (2004) 2.02
Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci U S A (2004) 1.99
Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med (2012) 1.99
Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson's and other conformational diseases? Neurobiol Aging (2005) 1.96
Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci (2004) 1.95
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One (2011) 1.93
Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet (2005) 1.92
The role of parkin in familial and sporadic Parkinson's disease. Mov Disord (2010) 1.90
The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci (2008) 1.86
A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. J Neurochem (2003) 1.82
Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc Natl Acad Sci U S A (2010) 1.81
Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. J Biol Chem (2007) 1.80
Role of nitric oxide in Parkinson's disease. Pharmacol Ther (2005) 1.77
The distinct role of medium spiny neurons and cholinergic interneurons in the D₂/A₂A receptor interaction in the striatum: implications for Parkinson's disease. J Neurosci (2011) 1.76
PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. J Neurochem (2004) 1.76
Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci (2005) 1.75